20.04.2020 • News

Concerns about Bayer’s Chloroquine Donation

Concerns About Bayer’s Chloroquine Donation (c) OJO Images RF/Getty Images
Concerns About Bayer’s Chloroquine Donation (c) OJO Images RF/Getty Images

The first international pharmaceutical company to offer free supplies of the malaria treatment hydroxychloroquine to the US government after President Donald Trump praised the drug as a potential COVID-19 treatment, Bayer’s donation of three million donated doses has come under scrutiny.

Reports from the US suggested that there have been quality concerns about the German group’s shipment, as the drugs were produced at facilities that didn't meet the FDA's quality standards.

Batches of the now generic malaria treatment developed by Bayer in the 1930s and marketed by it as Resochin were sourced from plants in India and in Karachi, Pakistan, sources told the Reuters news agency. And unlike the products donated by some other drugmakers, Resochin is not approved by the FDA even as an antimalarial.

The Bayer plant at Karachi is said to have been cited by the FDA for "gross failure" in its manufacturing processes, while the Resochin plant in India operated by Ipca Laboratories has not been evaluated by the FDA. At other of its facilities, Ipca reportedly was accused of data manipulation.

Despite the concerns, the FDA in March, reacting to the demand surge that followed the president’s “recommendation” of the malaria drug to treat the coronavirus, lifted its five-year-ban on exports to the US from Ipca facilities so the company could supply hydroxychloroquine sulfate and chloroquine phosphate APls, along with hydroxychloroquine sulfate tablets, to the US.

The US market is now running short of hydroxychloroquine, due to Trump’s campaign. Other than the drugs donated by Bayer and other drugmkers including Sandoz, Mylan, Teva and Sanofi, all of the US supply comes from Ipca and Indian compatriot Natco Pharma, according to Reuters.

In the wake of limitations on API supply during the COVID-19 outbreak in China, India said recently it was working on a plan to ramp up its own production to challenge Chinese dominance in the market. Around 70% of India's imports of APIs reportedly come from China.

 

Book

Innovation Management in Sustainable Chemistry

Innovation Management in Sustainable Chemistry

Comprehensive resource on sustainable chemistry, bridging the skill gap between academic science education and innovation and entrepreneurship

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.